J&J Abandons Addex-Partnered Epilepsy Candidate After Phase II Failure

1. Phase II Failure: Addex Therapeutics and Johnson & Johnson's investigational modulator ADX71149 failed to meet its primary endpoint in a Phase II epilepsy study, leading to a significant drop in Addex's stock price.
2. Mechanism of Action: ADX71149 is a positive allosteric modulator (PAM) of the metabotropic glutamate subtype 2 receptor, which plays a key role in seizure initiation and spread.
3. Trial Details: The placebo-controlled Phase II trial enrolled 110 patients with focal onset seizures and did not achieve statistical significance for the primary endpoint of time to reach baseline seizure count.
4. Future Plans: Addex will focus on its other PAM programs, including the Indivior-partnered GABAB PAM asset and the dipraglurant program for post-stroke sensorimotor recovery.
5. J&J's Decision: After reviewing the failed Phase II data, Johnson & Johnson has decided to halt development of the ADX71149 program.